clonidine has been researched along with Parkinson Disease in 33 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clonidine-growth hormone test (CGHT) has been proposed as a means of differentiating multiple system atrophy (MSA) from idiopathic Parkinson's disease (PD)." | 7.71 | Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. ( Kim, BJ; Lee, EA; Lee, WY, 2002) |
| "Clonidine, a centrally active alpha 2-adrenoreceptor agonist used to lower blood pressure, has been proposed to differentiate central from peripheral autonomic deficits and multiple system atrophy (MSA) from untreated idiopathic Parkinson's disease (IPD)." | 7.70 | Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease? ( Echaniz-Laguna, A; Guiraud-Chaumeil, C; Tranchant, C; Warter, JM, 2000) |
| " Clonidine hydrochloride, an antihypertensive drug believed to directly stimulate brain norepinephrine receptors, was administered to a group of patients with relatively mild Parkinson disease and coexisting essential hypertension and to three patients with Parkinson disease manifesting the "on-off" response to levodopa." | 7.65 | Clonidine in Parkinson disease. ( Marsden, CD; Parkes, JD; Tarsy, D, 1975) |
| "Clonidine is a centrally active alpha 2-adrenoceptor agonist that raises concentrations of GH in serum in healthy people and those with pure autonomic failure (with peripheral lesions), but not in those with MSA (with a central autonomic deficit)." | 5.30 | Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. ( Kimber, JR; Mathias, CJ; Watson, L, 1997) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "The clonidine-growth hormone test (CGHT) has been proposed as a means of differentiating multiple system atrophy (MSA) from idiopathic Parkinson's disease (PD)." | 3.71 | Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. ( Kim, BJ; Lee, EA; Lee, WY, 2002) |
| "Clonidine has been proposed to differentiate multiple system atrophy (MSA) from idiopathic Parkinson's disease (IPD), as it does not increase growth hormone (GH) release in MSA." | 3.71 | Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. ( Barone, P; Colao, AM; De Michele, G; Faggiano, A; Filla, A; Pellecchia, MT; Pivonello, R; Salvatore, E, 2001) |
| "Clonidine, a centrally active alpha 2-adrenoreceptor agonist used to lower blood pressure, has been proposed to differentiate central from peripheral autonomic deficits and multiple system atrophy (MSA) from untreated idiopathic Parkinson's disease (IPD)." | 3.70 | Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease? ( Echaniz-Laguna, A; Guiraud-Chaumeil, C; Tranchant, C; Warter, JM, 2000) |
| " Clonidine hydrochloride, an antihypertensive drug believed to directly stimulate brain norepinephrine receptors, was administered to a group of patients with relatively mild Parkinson disease and coexisting essential hypertension and to three patients with Parkinson disease manifesting the "on-off" response to levodopa." | 3.65 | Clonidine in Parkinson disease. ( Marsden, CD; Parkes, JD; Tarsy, D, 1975) |
| "Clonidine was well tolerated but our study was not enough powerful to demonstrate significant superiority compared to placebo in reducing ICDs despite a greater reduction of total QUIP score at 8 weeks." | 3.30 | Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial. ( Anheim, M; Ballanger, B; Bin, S; Boulinguez, P; Caire, C; Danaila, T; Dhelens, C; Duchez, DD; Fatisson, M; Giordana, C; Huddlestone, M; Klinger, H; Laurencin, C; Marques, A; Meoni, S; Nourredine, M; Prange, S; Thobois, S; Timestit, N; Vidal, T, 2023) |
| "The loss of dopaminergic cells during Parkinson's disease (PD) produces "frontal"-like impairment in spatial working memory (SWM) and planning functions." | 2.69 | Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease. ( Riekkinen, M; Riekkinen, P, 1999) |
| "Idiopathic Parkinson's disease (IPD) is a common neurodegenerative disorder whose differential diagnosis from other forms of atypical parkinsonism, for instance multiple system atrophy (MSA) or progressive supranuclear palsy, may be difficult, especially in the early stages." | 2.43 | Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. ( Barone, P; Colao, A; Pellecchia, MT; Pivonello, R, 2006) |
| "Clonidine is an anti-hypertensive medication which acts as an alpha-adrenergic receptor agonist." | 1.48 | Clonidine modulates the activity of the subthalamic-supplementary motor loop: evidence from a pharmacological study combining deep brain stimulation and electroencephalography recordings in Parkinsonian patients. ( Albares, M; Ballanger, B; Boulinguez, P; Broussolle, E; Lau, B; Lio, G; Spay, C; Thobois, S, 2018) |
| "She had been treated for Parkinson's disease at the neurology department of another university hospital for 9 years." | 1.39 | Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report. ( Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T, 2013) |
| "Multiple System Atrophy (MSA) and idiopathic Parkinson's disease (PD) can be difficult to distinguish." | 1.31 | Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with striatonigral degeneration. ( Horstink, MW; Lenders, JW; Oyen, WJ; Strijks, E; Sweep, F; van't Hof, M, 2002) |
| "Clonidine is a centrally active alpha 2-adrenoceptor agonist that raises concentrations of GH in serum in healthy people and those with pure autonomic failure (with peripheral lesions), but not in those with MSA (with a central autonomic deficit)." | 1.30 | Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. ( Kimber, JR; Mathias, CJ; Watson, L, 1997) |
| "Clonidine was also effective in stimulating spatial working memory after withdrawal of dopaminergic drugs, and when this was done, its effect was greater in severe Parkinson's disease patients." | 1.30 | The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease. ( Jäkälä, P; Kejonen, K; Riekkinen, M; Riekkinen, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (24.24) | 18.7374 |
| 1990's | 9 (27.27) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 6 (18.18) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Wu, J | 1 |
| Yang, X | 1 |
| Cai, P | 1 |
| Liu, Q | 1 |
| Wang, KDG | 1 |
| Kong, L | 1 |
| Wang, X | 1 |
| Criaud, M | 1 |
| Laurencin, C | 2 |
| Poisson, A | 1 |
| Metereau, E | 1 |
| Redouté, J | 1 |
| Thobois, S | 3 |
| Boulinguez, P | 3 |
| Ballanger, B | 3 |
| Timestit, N | 1 |
| Marques, A | 1 |
| Duchez, DD | 1 |
| Giordana, C | 1 |
| Meoni, S | 1 |
| Huddlestone, M | 1 |
| Danaila, T | 1 |
| Anheim, M | 2 |
| Klinger, H | 1 |
| Vidal, T | 1 |
| Fatisson, M | 1 |
| Caire, C | 1 |
| Nourredine, M | 1 |
| Dhelens, C | 1 |
| Prange, S | 1 |
| Bin, S | 1 |
| Spay, C | 1 |
| Albares, M | 1 |
| Lio, G | 1 |
| Broussolle, E | 1 |
| Lau, B | 1 |
| Alves Do Rego, C | 1 |
| Namer, IJ | 1 |
| Marcel, C | 1 |
| Lefebvre, F | 1 |
| Lagha-Boukbiza, O | 1 |
| Renaud, M | 1 |
| Tranchant, C | 2 |
| Nomoto, S | 1 |
| Nakamura, M | 1 |
| Sato, T | 1 |
| Hisanaga, R | 1 |
| Jordan, J | 1 |
| Shibao, C | 1 |
| Biaggioni, I | 1 |
| Gerlach, M | 1 |
| Halley, P | 1 |
| Riederer, P | 1 |
| van den Buuse, M | 1 |
| Strijks, E | 1 |
| van't Hof, M | 1 |
| Sweep, F | 1 |
| Lenders, JW | 1 |
| Oyen, WJ | 1 |
| Horstink, MW | 1 |
| Lee, EA | 1 |
| Kim, BJ | 1 |
| Lee, WY | 1 |
| Pellecchia, MT | 3 |
| Pivonello, R | 3 |
| Salvatore, E | 2 |
| Faggiano, A | 2 |
| Barone, P | 3 |
| De Michele, G | 2 |
| Lombardi, G | 1 |
| Colao, A | 2 |
| Filla, A | 2 |
| Hiner, BC | 1 |
| Cash, R | 2 |
| Ruberg, M | 1 |
| Raisman, R | 1 |
| Agid, Y | 2 |
| O'Connor, DT | 1 |
| Cervenka, JH | 1 |
| Stone, RA | 1 |
| Parmer, RJ | 1 |
| Franco-Bourland, RE | 1 |
| Madrazo, I | 1 |
| Langlais, PJ | 1 |
| Zoukos, Y | 1 |
| Thomaides, T | 1 |
| Pavitt, DV | 1 |
| Cuzner, ML | 1 |
| Mathias, CJ | 4 |
| Kimber, JR | 2 |
| Watson, L | 2 |
| Riekkinen, M | 3 |
| Kejonen, K | 2 |
| Jäkälä, P | 2 |
| Soininen, H | 1 |
| Riekkinen, P | 3 |
| Clarke, CE | 1 |
| Ray, PS | 1 |
| Speller, JM | 1 |
| Guiraud-Chaumeil, C | 1 |
| Echaniz-Laguna, A | 1 |
| Warter, JM | 1 |
| Colao, AM | 1 |
| Kimber, J | 1 |
| Muthane, U | 1 |
| Shoulson, I | 2 |
| Chase, TN | 2 |
| Tarsy, D | 1 |
| Parkes, JD | 1 |
| Marsden, CD | 1 |
| Carlsson, M | 1 |
| Svensson, A | 1 |
| Carlsson, A | 1 |
| Berlan, M | 1 |
| Rascol, O | 1 |
| Belin, J | 1 |
| Moatti, JP | 1 |
| Rascol, A | 1 |
| Montastruc, JL | 1 |
| Sandyk, R | 1 |
| Lasbennes, F | 1 |
| Sercombe, R | 1 |
| Seylaz, J | 1 |
| Baumeister, AA | 1 |
| Frye, GD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de Parkinson[NCT01796483] | 37 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for clonidine and Parkinson Disease
| Article | Year |
|---|---|
Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Arginine; Clonidine; Diagnosis, Differential; Growth Hormone; Humans; Mul | 2006 |
The endogenous opioid system in neurological disorders of the basal ganglia.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clonidine; Endorphins; gamma-Aminobutyric Aci | 1985 |
The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome.
Topics: Adenine Nucleotides; Animals; Central Nervous System; Child; Child, Preschool; Clonidine; Corpus Str | 1985 |
4 trials available for clonidine and Parkinson Disease
| Article | Year |
|---|---|
Noradrenaline and Movement Initiation Disorders in Parkinson's Disease: A Pharmacological Functional MRI Study with Clonidine.
Topics: Clonidine; Humans; Magnetic Resonance Imaging; Movement; Norepinephrine; Parkinson Disease | 2022 |
Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial.
Topics: Clonidine; Disruptive, Impulse Control, and Conduct Disorders; Double-Blind Method; Humans; Impulsiv | 2023 |
Alpha2-adrenergic agonist clonidine for improving spatial working memory in Parkinson's disease.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Blood Pressure; Clonidine; F | 1999 |
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Clonidine; Female; Humans; Levodopa; Male; Middle Aged; P | 1976 |
26 other studies available for clonidine and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred S | 2016 |
Clonidine modulates the activity of the subthalamic-supplementary motor loop: evidence from a pharmacological study combining deep brain stimulation and electroencephalography recordings in Parkinsonian patients.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Brain Waves; Clonidine; Cues; Deep Brain Stimulation; El | 2018 |
Prospective study of relevance of
Topics: 3-Iodobenzylguanidine; Biomarkers; Clonidine; Diagnosis, Differential; Female; Follow-Up Studies; He | 2018 |
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report.
Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias | 2013 |
Multiple system atrophy: using clinical pharmacology to reveal pathophysiology.
Topics: Atomoxetine Hydrochloride; Autonomic Nervous System; Clonidine; Diagnosis, Differential; Drug Therap | 2015 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with striatonigral degeneration.
Topics: Aged; Analysis of Variance; Chi-Square Distribution; Clonidine; Diagnosis, Differential; Growth Horm | 2002 |
Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography.
Topics: Aged; Anal Canal; Clonidine; Diagnosis, Differential; Electromyography; Female; Human Growth Hormone | 2002 |
Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.
Topics: Arginine; Case-Control Studies; Clonidine; Diagnosis, Differential; Female; Growth Hormone; Growth H | 2005 |
Differential diagnosis of Parkinson's disease: a new blood test?
Topics: Adrenergic alpha-Agonists; Arginine; Clonidine; Diagnosis, Differential; Growth Hormone; Humans; Mul | 2006 |
Adrenergic receptors in Parkinson's disease.
Topics: Clonidine; Dihydroalprenolol; Frontal Lobe; Humans; Locus Coeruleus; Neural Pathways; Norepinephrine | 1984 |
Chromogranin A immunoreactivity in human cerebrospinal fluid: properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amino Acid Sequence; Brain Diseases; Chromogranin A; Chrom | 1993 |
Beta-adrenoceptor expression on circulating mononuclear cells of idiopathic Parkinson's disease and autonomic failure patients before and after reduction of central sympathetic outflow by clonidine.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Clonidine; Female; Humans; Leukocytes, Mononuclear; | 1993 |
Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine.
Topics: Adrenergic alpha-Agonists; Atrophy; Autonomic Nervous System Diseases; Clonidine; Diagnosis, Differe | 1997 |
Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease.
Topics: Aged; Attention; Case-Control Studies; Clonidine; Dopamine; Female; Humans; Male; Middle Aged; Movem | 1998 |
Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Aged; Atrophy; Autonomic Nervous System Diseases; Clonidine; Diagnosis, D | 1999 |
The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Aged; Antiparkinson Agents; Attention; Blood Pressure; Clonidine; Dopamin | 1999 |
Clonidine-growth-hormone testing in Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Clonidine; Diagnosis, Differential; Growth Hormone; Humans; Parkinson Dis | 1999 |
Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?
Topics: Aged; Aged, 80 and over; Clonidine; Diagnosis, Differential; Female; Growth Hormone; Humans; Male; M | 2000 |
Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia.
Topics: Adrenergic alpha-Agonists; Arginine; Clonidine; Diagnosis, Differential; Drug Administration Schedul | 2001 |
Is clonidine-growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?
Topics: Clonidine; Diagnosis, Differential; Growth Hormone; Humans; Multiple System Atrophy; Parkinson Disea | 2002 |
Clonidine in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Clonidine; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Pa | 1975 |
Dopaminergic mechanisms in patients with extrapyramidal disease.
Topics: Animals; Biogenic Amines; Brain; Caffeine; Clonidine; Dopamine; Drug Evaluation; Drug Therapy, Combi | 1975 |
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.
Topics: Adrenergic alpha-Agonists; Animals; Atropine; Biperiden; Clonidine; Disease Models, Animal; Dizocilp | 1991 |
Alpha 2-adrenergic sensitivity in Parkinson's disease.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Clonidine; Fatty Acids, Nonesterified; Female; Growth Ho | 1989 |
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects.
Topics: Aged; Alprenolol; Capillaries; Cerebrovascular Circulation; Clonidine; Dihydroalprenolol; Humans; Ki | 1985 |